How does VK2735's mechanism as a dual GLP-1/GIP receptor agonist potentially benefit patients with obesity, compared to other existing treatments?

Can you discuss the significance of the dose-dependent weight reduction observed in the VK2735 study, and how it may influence future dosing strategies?

Given the reported tolerability of VK2735, how does its safety profile stand out in comparison to other drugs in its class, especially regarding gastrointestinal side effects?

Based on the preliminary evaluation suggesting longer treatment durations with VK2735 may yield further weight reductions, what are your expectations for its long-term efficacy and patient adherence?

How do the exploratory pharmacodynamic measures from the Phase 1 study, like body weight changes, inform us about VK2735's potential clinical application in obesity management?

Could you elaborate on the importance of the placebo-adjusted mean weight loss results in VK2735's study, particularly in the context of clinical relevance?

Considering the proportion of subjects achieving significant weight loss with VK2735, how might this impact patient outcomes and expectations in a real-world setting?

With Phase 2 trials planned, what are the anticipated next steps for VK2735's development, and what should clinicians and patients expect in terms of its advancement and availability in treating obesity?